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Perioperative topical bovine thrombin exposure is not associ-
ated with hemodialysis graft thrombosis. Arteriovenous (AV)
graft use as hemodialysis access remains highly prevalent, with
a consequent high thrombosis rate. The magnitude of this prob-
lem requires that all potentially modifiable risk factors for graft
thrombosis be thoroughly investigated. During graft surgery,
topical bovine thrombin is often administered, which can lead
to the development of antibovine thrombin antibodies and sub-
sequent hemostatic changes. A recent study correlated the pres-
ence of plasma antibovine thrombin antibodies with graft throm-
bosis in hemodialysis patients. We therefore hypothesized that
perioperative topical bovine thrombin exposure would lead to
the development of antibovine thrombin antibodies and graft
thrombosis. We screened 314 hemodialysis patients and identi-
fied 73 patients who had 74 grafts placed for whom complete
data on perioperative topical bovine thrombin exposure and
subsequent graft outcomes was available. Sixty-one of these
patients were available for retrospective measurement of anti-
bovine thrombin antibodies, antihuman thrombin antibodies,
and the thrombin activation markers thrombin activatible fibrin-
olysis inhibitor (TAFI) and thrombin precursor protein (TpP).
In these grafts, there was no significant association between
topical bovine thrombin exposure and primary assisted patency
(P  0.37). The presence of antibovine thrombin antibodies
(P  0.13), antihuman thrombin antibodies (P  0.10), and
increased TAFI (P 0.18) were associated with trends toward
reduced primary assisted patency which did not reach signifi-
cance. There was a correlation between antibovine thrombin
antibodies and antihuman thrombin antibodies (r  0.30, P 
0.0001) and between TAFI and TpP (r  0.30, P  0.0001),
but no significant correlation between topical bovine thrombin
exposure and elevated levels of antibovine thrombin antibod-
ies, antihuman thrombin antibodies, TAFI or TpP. We con-
clude that perioperative topical bovine thrombin exposure is
not associated with subsequent graft thrombosis.
Hemodialysis access failure is associated with signifi-
cant patient morbidity, inconvenience and economic cost
[1]. The current array of available interventions with
demonstrated efficacy to reduce thrombosis of arteriove-
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nous (AV) grafts, the most commonly placed permanent
vascular access in United States hemodialysis patients,
is limited. Pharmacologic prevention of graft thrombosis
holds great potential and remains under study [2–4] (ab-
stracts; Dember, et al, J Am Soc Nephrol, 13:229A; and
Dixon, et al, J Am Soc Nephrol, 13:232A). Strategies
to angioplasty grafts identified prophylactically through
surveillance programs can extend graft life and reduce
access-related morbidity and costs [5–8]. However, reste-
nosis is common and costs associated with maintaining
vascular access patency are extensive. Efforts to place a
higher percentage of native AV fistulas, particularly in
the United States, have been recommended and are of
paramount importance [9, 10]. Despite these advances,
vascular access remains the Achilles heel of the hemodi-
alysis procedure, and every promising approach to reduc-
ing access complications should be explored.
Against this background, Sands et al [11] recently iden-
tified a strong correlation between hemodialysis access
graft thrombosis and the presence of elevated antibovine
thrombin antibody levels. In a retrospective study, ele-
vated levels of antibovine thrombin antibodies were
found in 84.6% of patients with a history of thrombosed
AV grafts versus only 13.3% in those without a history
of thrombosis. Topical bovine thrombin is frequently
applied in vascular procedures using synthetic grafts to
achieve hemostasis at the anastomosis suture line and
has been associated with the development of coagulation
abnormalities [12, 13]. This has led to the hypothesis
that perioperative topical bovine thrombin administra-
tion causes the development of antibovine thrombin anti-
bodies and graft thrombosis and is a potentially modifi-
able cause of AV graft thrombosis [11].
In order to investigate this hypothesis, we studied the
vascular access history of a cohort of patients who had
an AV graft placed for hemodialysis access for whom
detailed surgical history and subsequent access function
history was available We examined the relationship be-
tween perioperative topical bovine thrombin administra-
tion, the subsequent development of antibovine throm-
bin antibodies, and subsequent graft thrombosis. We also
retrospectively measured several recently identified mark-
ers of activation of the thrombin system in the same cohort.
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Fig. 1. Patient enrollment.
METHODS
Patients
The initial study population screened consisted of 314
hemodialysis patients at four outpatient hemodialysis
units served by the nephrology faculty at the Maine Med-
ical Center for whom follow-up information concerning
vascular access was readily available. Of these 314 pa-
tients, 90 patients were identified who had 91 AV grafts
created at the Maine Medical Center over the period
October 1, 1994 through June 31, 2000. The remaining
224 patients were excluded on the basis of having an
AV fistula or dialysis catheter as dialysis access, or by
having had placement of an AV graft outside the Maine
Medical Center. The majority of these patients have a
functioning fistula, consistent with an aggressive ap-
proach to fistula placement at our institution. Of the 90
patients with AV grafts, patients were excluded on the
basis of incomplete or inconsistent surgical records (N
4), or incomplete access intervention or procedure re-
cords (N 9). Four patients with early, irreversible graft
failure (48 hours) were regarded as likely surgical fail-
ures and also excluded. A total of 74 grafts in 73 patients
were included in the final analysis. (Fig. 1) Patient char-
acteristics are further defined in Table 1. Maine Medical
Center Internal Review Board approval was obtained
and informed patient consent was obtained prior to
blood collection. Blood samples from patients giving in-
formed consent were obtained predialysis during the
study period.
Analysis of bovine thrombin exposure
Topical bovine thrombin for surgical use is obtained
from Jones Pharma, Inc. (St. Louis, MO, USA). Op-
erating room nursing charts in which all medications
administered were charted were used as the primary
means of identifying topical bovine thrombin administra-
tion at the time of graft creation. In every case, this
data were validated using dictated surgeons’ operative
reports. A total of six surgeons placed 100% of the grafts
during this study. Significant intersurgeon variation in
bovine thrombin use was noted, with three surgeons
never using topical bovine thrombin and three surgeons
using topical bovine thrombin in 50% of cases. As a
further validating approach, all of the surgeons involved
were queried regarding the frequency of their use of
topical bovine thrombin in graft creation. Their assess-
ments were highly consistent with the charted data, sup-
porting the accuracy of the retrospective chart review
techniques.
Serologic markers of thrombin activation
Thrombin precursor protein (TpP) was analyzed uti-
lizing the TpP enzyme-linked immunosorbent assay
(ELISA) (American Biogenetic Sciences, Copiague, NY,
USA) [14]. Thrombin activatible fibrinolysis inhibitor
(TAFI) ELISA was performed by using a commercial
kit (Imuclone; TAFI ELISA Kit, American Diagnostica,
Greenwich, CT, USA) [15]. Antibody to the topical bo-
vine thrombin and human thrombin were detected by
ELISA method that has been described by Sands et al
[11]. Briefly, topical bovine thrombin (Jones Pharma,
Inc.) or purified human thrombin (Stago Diagnostica,
Parsippany, NJ, USA) was diluted 1:100 in phosphate-
buffered saline (PBS), pH7.4, coated onto n-ticrotiter
wells, and incubated overnight at 4oC. The wells were
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Table 1. Patient demographics
Bovine thrombin exposure No (N  41) Yes (N  33) Total (N  74) P value
Gender male % 25 (61) 11 (33) 36 (47) 0.02
Patient age years 67.6 73.2 70.1 0.96
Time on dialysis days 987 1318 1135 0.88
Co-morbidities %
Diabetes 15 (36.6) 27 (36.5) 12 (36.4) 0.99
Coronary artery disease 21 (51.2) 21 (63.6) 42 (56.8) 0.29
Congestive heart failure 14 (34.1) 11 (33.3) 25 (33.8) 0.94
Hypertension 35 (85.4) 23 (69.7) 58 (78.4) 0.11
Peripheral vascular disease 12 (29.3) 13 (39.4) 25 (33.8) 0.36
Cerebrovascular accident 9 (22.0) 9 (27.3) 18 (24.3) 0.60
Cardiothoracic surgery 11 (26.8) 9 (27.3) 20 (27.0) 0.55
Peripheral vascular surgery 6 (14.6) 6 (18.2) 12 (16.2) 0.68
blocked with 0.25% nonfat dry milk/0.2% Tween 20
(Sigma Chemical Co., St. Louis, MO) in PBS (blocking
buffer) for 2 hours, then incubated with 50 L of a 1:10
dilution of patient serum in blocking buffer for 1 hour
at 37oC. Bound immunoglobulin (Ig) was detected with
alkaline phosphatase-conjugated human IgG. A positive
result was defined as more than three standard deviations
greater than the normal mean. Forty-two normal healthy
subjects were used to obtain the TpP normal reference
range. The normal reference range is 0 to 3.33 g/mL.
The normal reference range for TAFI, 46% to 146%, was
obtained from 30 normal healthy donors. The normal
reference ranges for antibody against bovine thrombin
[0 to 0.41 optical density (OD)] and human thrombin (0
to 0.16 OD), were similarly obtained from 30 normal
healthy donors.
Clinical end points
Hemodialysis unit charts of the study patients were
reviewed. AV grafts identified as placed within 30 days
of dialysis initiation were considered first grafts (N 
40), while patients with an AV graft placed more than
30 days after dialysis initiation (N  31) were assumed
to have had a prior graft, although documentation was
not always clear in this group. Graft outcome data, in-
cluding incidence of graft thrombosis, angioplasty,
thrombolyis, surgical thrombectomy, and revision as well
as graft abandonment and new graft creation were re-
corded. All available radiology, surgery, and hospital
records were compared to previously compiled dialysis
access logs as well as to monthly dialysis unit progress
notes for internal consistency. This data were used to
compile graft thrombosis, interventional and surgical
procedures, and patency rates. Time on dialysis was de-
termined from the initiation of dialysis to the end of the
study.
Primary unassisted patency is defined as the time from
creation of a new hemodialysis graft until a clinical inter-
vention to maintain graft function is performed or graft
thrombosis occurs. Clinical interventions include angio-
plasty, surgical revision, surgical thrombectomy, or me-
chanical thrombolysis. Primary assisted patency is de-
fined as the time from creation of a new hemodialysis
graft until the first episode of graft thrombosis, whether
or not intervening angioplasty or surgical revision has
occurred. The study end points were chosen because of
their clinical relevance and acceptance in the hemodialy-
sis graft literature [16].
Data analysis
Differences in baseline clinical characteristics between
patients who did and did not have perioperative topical
bovine thrombin exposure were assessed using chi-square
tests for categorical variables and t tests or nonparamet-
ric equivalents, as appropriate, for continuous variables.
The major predictor of interest is bovine thrombin
exposure. Secondary predictors of interest include inves-
tigational serologic markers of activation of the thrombin
system. Because follow-up times varied in this observa-
tional study, we compared primary assisted patency rates
in the groups of interest using Kaplan-Meier analysis
and the Wilcoxon test. The SAS and Microsoft Excel
software packages were used.
RESULTS
Primary assisted patency was analyzed with respect to
charted bovine thrombin administration (Fig. 2). There
was no significant difference in primary assisted patency
based on exposure to topical bovine thrombin (P 0.37).
The rate of graft thrombosis was 0.70 thromboses per
patient per year in the group without bovine thrombin
exposure and 0.60 thromboses per patient per year in
the group with bovine thrombin exposure. The 1-year
thrombosis rates for all patients (44%), and life table
secondary patency rates for all patients at 1 year (86%)
and 2 years (72%) were consistent with those reported
in the literature as well, suggesting accurate capture of
graft events [17–20]. The number of vascular access pro-
cedures per patient per year were also similar between
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Fig. 2. Kaplan-Meier analysis of primary assisted patency based on
presence or absence of perioperative bovine thrombin exposure.
patients with bovine thrombin exposure (1.01 procedures
per patient per year) and without (1.26 procedures per
patient per year, P  0.49).
Patient demographics were remarkable for a higher
percentage of men in the group without bovine thrombin
exposure than in the group with bovine thrombin expo-
sure, suggesting that bovine thrombin may have been
preferentially administered to women. Univariate analy-
sis of the thrombosis rate by gender and age did not
yield significant differences (P  0.58 for gender, P 
0.13 for age). The group without bovine thrombin expo-
sure had a trend toward shorter average time on dialysis
(32.5 months) than did the group with bovine thrombin
exposure (43.3 months). Reanalysis of the data after
censoring long-term survivors in the group with bovine
thrombin exposure also did not demonstrate significant
differences in thrombosis rates (P  0.51).
An attempt was made to account for the effect of
possible topical bovine thrombin administration outside
of the index graft procedure. The data were reanalyzed
by including first grafts only (N  40), and no significant
differences in thrombosis were noted (P  0.53). Simi-
larly, by controlling for prior cardiothoracic and periph-
eral vascular surgery, in which topical bovine thrombin
is frequently used, no significant differences in outcomes
were noted (P  0.21). There were also no significant
differences in thrombosis rates between individual sur-
geons.
Of the 73 patients enrolled in this study, 61 patients
(84%) were available and consented to have blood mea-
surements of antibodies to bovine thrombin, human
thrombin, as well as serologic measures of activation of
the thrombin system. Of 61 patients, 33 (54%) did not
have evidence of prior topical bovine thrombin exposure,
while 28 (46%) did have evidence of topical bovine
thrombin exposure on chart review. Sixteen of the 61
patients (26%) had detectable circulating antibovine
Table 2. Perioperative bovine thrombin administration (BT), and
markers of thrombin activation
No BT exposure Yes BT exposure P value
ABTAB 8/33 (24%) 8/28 (29%) 0.7
AHTAB 8/33 (24%) 3/28 (11%) 0.17
TAFI 6/33 (18%) 4/28 (14%) 0.68
TpP 17/33 (52%) 20/36 (56%) 0.73
Abbreviations are: ABTAB, antibovine thrombin antibodies; AHTAB, anti-
human thrombin antibodies; TAFI, thrombin activatible fibrinolysis inhibitor;
TpP, thrombin precursor protein.
thrombin antibodies, while 11 patients (18%) had detect-
able circulating antihuman thrombin antibodies. Table
2 demonstrates the relationship between topical bovine
thrombin exposure during graft surgery and the presence
or absence of detectable circulating antibovine thrombin
antibodies or antihuman thrombin antibodies. Eight of
33 patients without topical bovine thrombin exposure
(24%) had detectable circulating antibovine thrombin
antibodies, while eight of 28 (29%) patients with bovine
thrombin exposure had evidence of detectable circulat-
ing antibovine thrombin antibodies (P  0.70 for rela-
tionship of topical bovine thrombin exposure and antibo-
vine thrombin antibodies). Similarly, there were no
significant differences in the presence of detectable circu-
lating antihuman thrombin antibodies as a function of
surgical topical bovine exposure (24% without bovine
thrombin exposure versus 11% with bovine thrombin
exposure, P  0.17).
The relationship between the presence of detectable
circulating antibovine thrombin antibodies and antihu-
man thrombin antibodies with clinical vascular access
thrombotic events were examined. Figure 3 demon-
strates a trend toward improved early primary assisted
patency in patients with normal antibovine thrombin
antibodies compared to elevated antibovine thrombin
antibodies (P  0.13). Figure 4 demonstrates similar
findings with respect to the presence or absence of anti-
human thrombin antibodies. There was a strong but in-
significant trend toward earlier thrombosis in patients
with elevated antihuman thrombin antibodies (P 0.10).
There was also a significant correlation between the pres-
ence of antibovine thrombin antibodies and antihuman
thrombin antibodies (r  0.30, P  0.0001).
The relationship between topical bovine thrombin ex-
posure during graft surgery and levels of TAFI and
TpP were examined (Table 2). Overall, 10 of 61 pa-
tients (16%) had elevated plasma TAFI levels compared
to healthy subjects, while 37 of 61 subjects (61%) had
elevated levels of TpP. There was a significant correla-
tion between patients with elevated TAFI and TpP
(r  0.30, P  0.0001). However, there were no signifi-
cant differences in the likelihood of elevated TAFI or
TpP as a function of topical bovine thrombin exposure
during graft surgery.
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Fig. 3. Kaplan-Meier analysis of primary assisted patency based on pres-
ence or absence of detectable antibovine thrombin antibodies (ABTAB).
Fig. 4. Kaplan-Meier analysis of primary assisted patency based on
presence or absence of antihuman thrombin antibodies (AHTAB).
Figures 5 and 6 examine the relationship between ele-
vations in plasma TAFI and TpP and primary assisted
patency. There was a trend for an elevated TAFI level
to be associated with lower rate of primary assisted pat-
ency (P  0.18) and for elevated TpP to be associated
with improved primary assisted patency (P  0.07), but
neither reached significance. Mean TAFI levels also did
not differ significantly between patients with a clinical
history of thrombosis (102  46.3%) and those without
(109.8 47.1%). Similarly, 60% of patients without clini-
cal evidence of thrombosis had elevated TpP levels in
comparison to 56% of patients with clinical evidence of
vascular access thrombosis (P  0.73). The mean TpP
was similar in patients with a clinical history of thrombo-
sis (4.99  5.00 g/mL) compared to those without
(4.09  3.1 g/mL).
Fig. 5. Kaplan-Meier analysis of primary assisted patency based on
presence or absence of elevated thrombin activatible fibrinolysis inhibi-
tor (TAFI) levels.
Fig. 6. Kaplan-Meier analysis of primary assisted patency based on
presence or absence of thrombin precursor protein (TpP).
DISCUSSION
In this study, no association was found between AV
graft thrombosis in hemodialysis patients and exposure
to topical bovine thrombin during access creation sur-
gery. Thus, these results do not support the hypothesis
that topical bovine thrombin administration at the time
of hemodialysis vascular access creation is a potentially
modifiable risk factor for subsequent graft dysfunction
in hemodialysis patients.
In a previous investigation, the presence of antibodies
to topical bovine thrombin correlated with previous vas-
cular access thrombosis. In that study, 13 of 28 patients
with AV grafts (46%) had clinically detectable elevated
antibovine thrombin antibodies. Eleven of these 13 pa-
tients (85%) had a history of prior access thrombosis in
comparison to two of 15 (13%) of patients with polytetra-
fluoroethylene (PTFE) grafts without elevated antibody
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levels to topical bovine thrombin. Of interest, in this
earlier study, the presence of elevated antibody levels
to topical bovine thrombin was not associated with in-
creased thrombosis rate in patients with native AV fistu-
las or in patients with cuffed, subcutaneously tunneled
catheters. The overall incidence of elevated antibody
levels to topical bovine thrombin in this earlier hemodial-
ysis patient cohort (31%) was similar to that observed
in our patient population (26%). This percentage is also
comparable to a recent study in which 24% of patients
undergoing cardiac valvular surgery had elevated anti-
body levels to topical bovine thrombin measured preop-
eratively. [21]
In comparison to the earlier study, the sample size of
patients with grafts in our study was substantially larger.
A strong but insignificant trend toward earlier thrombo-
sis in patients with the presence of antibovine thrombin
was noted in the present study, albeit there was no corre-
lation with exposure to topical bovine thrombin during
access creation surgery. Instead, there was a significant
correlation between the presence of antibovine thrombin
antibodies and antihuman thrombin antibodies, which
were also associated with a trend toward an increased
early thrombosis rate. Thus, the results of the present
study suggest that the development of antibovine throm-
bin antibodies may be a marker of a propensity toward
antibody formation and hypercoagulability, rather than
defining a modifiable risk factor for access thrombosis
at the time of surgery.
In this study, we also examined plasma levels of TAFI.
TAFI is a recently described inhibitor of fibrinolyis that
can be activated by the thrombin/thrombomodulin com-
plex-catalyzed proteolysis to a carboxypeptidase B-like
enzyme [22, 23]. TAFI is activated by relatively high
concentrations of thrombin that exceed the thrombin
concentration required for fibrin formation. The demon-
stration that activation of TAFI requires intact intrinsic
coagulation pathway has led to the suggestion that
plasma TAFI levels can be used as a marker of in vivo
thrombin activation [24, 25]. The finding in this study
that 16% of hemodialysis patients with AV grafts have
elevated plasma TAFI levels supports the concept that
hemodialysis patients frequently experience activation
of the thrombin system. Elevated TAFI levels were also
associated with a trend toward access thrombosis, sug-
gesting that propensity to thrombin activation contrib-
utes to a loss of primary access patency.
The TpP assay is an ELISA-based method to mea-
sure desAA fibrin and desAABB fibrin, the soluble poly-
mers and precursors of insoluble fibrin. [26] An increase
in TpP is indicative of the increased generation of
thrombin and its interaction with fibrinogen to form fi-
brin [27–29]. Increased TpP seems to be more indica-
tive of an impending vascular event. The TpP has been
found to have 100% negative predictive value in the
exclusion of patients with proximal deep vein thrombosis
and pulmonary embolism. [30] The presence of elevated
TpP levels in the majority of hemodialysis patients
with AV grafts in this study further supports the concept
that low level thrombin activation is a frequent occur-
rence in this patient population. The higher prevalence
of elevated TpP compared to TAFI in this patient
cohort is not unexpected, given the higher degree of
thrombin activation required to activate TAFI compared
to TpP. However, the finding that a higher TpP was
associated with a trend toward improved access survival
was surprising and difficult to explain.
Several limitations of the present study should be rec-
ognized. First, it is a retrospective study and thus it is
possible that not all directly relevant clinical information
concerning topical bovine thrombin exposure during vas-
cular access surgery has been obtained. However, the
internal consistency between nursing notes, operative
reports, and individual surgeons’ self-reported use of
topical bovine thrombin suggest that the data obtained
are valid. With respect to detection of antibodies to topi-
cal bovine thrombin, it should be noted that blood sam-
ples in the study were not obtained in the time period
immediately before and after vascular access creation.
Furthermore, in the intervening time between dialysis
access creation and the measurement of antithrombin
antibodies, patients may have undergone procedures
with exposure to bovine thrombin, thereby reducing the
ability to demonstrate a relationship between bovine
thrombin exposure and antibody formation. A recent
study has emphasized the temporal relation between top-
ical bovine thrombin exposure and the development of
antitopical bovine thrombin antibodies in patients un-
dergoing cardiac surgery [21]. Thus, it is possible that
earlier in the clinical course patients who had graft
thrombosis may have had higher levels of detectable
antibovine thrombin antibodies. However, the method-
ology used in this study is similar to that in the study by
Sands et al [11], albeit with a larger patient cohort with
grafts in the present study.
CONCLUSION
We have examined the hypothesis that topical bovine
thrombin administration at the time of hemodialysis vas-
cular access surgery contributes to the development of
antibodies to bovine thrombin and subsequent loss of
primary assisted patency. This study finds no association
between hemodialysis graft thrombosis and bovine throm-
bin exposure. Studies of serologic markers of thrombin
activation suggest that hemodialysis patients with AV grafts
experience a generalized increase in thrombin activation
with a trend toward correlation with graft thrombosis.
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